Latanoprost punctal plug - Mati Therapeutics

Drug Profile

Latanoprost punctal plug - Mati Therapeutics

Alternative Names: L-PPDS

Latest Information Update: 03 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator QLT
  • Developer Mati Therapeutics
  • Class Antiglaucomas; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glaucoma; Ocular hypertension

Most Recent Events

  • 25 Apr 2017 Mati Therapeutics has patent protection for Evolute® punctal plug delivery system in USA and major international countries
  • 25 Apr 2017 Mati Therapeutics receives patent allowance for Evolute® punctal plug delivery system in USA
  • 01 Dec 2016 Mati Therapeutics completes a phase II trial for Ocular hypertension and Glaucoma in USA (NCT02014142)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top